Söndag 27 April | 04:25:43 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-20 08:00 Kvartalsrapport 2025-Q3
2025-08-28 08:00 Kvartalsrapport 2025-Q2
2025-05-30 N/A X-dag ordinarie utdelning LIDDS 0.00 SEK
2025-05-29 08:00 Kvartalsrapport 2025-Q1
2025-05-28 N/A Årsstämma
2025-02-20 - Bokslutskommuniké 2024
2024-11-21 - Kvartalsrapport 2024-Q3
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-05-16 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2024-05-15 - Årsstämma
2024-02-27 - Extra Bolagsstämma 2024
2024-02-22 - Bokslutskommuniké 2023
2023-11-28 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-05-30 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2023-05-29 - Årsstämma
2023-05-29 - Kvartalsrapport 2023-Q1
2023-03-13 - Bokslutskommuniké 2022
2023-01-09 - Extra Bolagsstämma 2022
2022-11-28 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-02 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2022-06-01 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-22 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-18 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2021-05-18 - Kvartalsrapport 2021-Q1
2021-05-17 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-15 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2020-05-14 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-28 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-05-17 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-29 - Kvartalsrapport 2018-Q3
2018-08-30 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2018-05-16 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-11-09 - Kvartalsrapport 2017-Q3
2017-10-06 - Extra Bolagsstämma 2017
2017-08-31 - Kvartalsrapport 2017-Q2
2017-05-12 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2017-05-11 - Årsstämma
2017-05-11 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016
2016-10-27 - Kvartalsrapport 2016-Q3
2016-08-24 - Kvartalsrapport 2016-Q2
2016-06-09 - Extra Bolagsstämma 2016
2016-04-22 - Årsstämma
2016-04-22 - Kvartalsrapport 2016-Q1
2016-04-21 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2016-02-10 - Bokslutskommuniké 2015
2015-10-29 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-04-22 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2015-04-21 - Årsstämma
2015-04-21 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-11-11 - Kvartalsrapport 2014-Q3
2014-08-21 - Kvartalsrapport 2014-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
LIDDS är ett läkemedelsbolag. Bolaget utvecklar läkemedelsprodukter baserade på en patentskyddad och kliniskt testad drug delivery-teknologi. Egenskaperna hos produkterna utgör grunden för LIDDS teknologiplattform för utveckling av injicerbara läkemedelsprodukter. LIDDS är förkortningen för Local Intelligent Drug Delivery System och bolaget har sitt huvudkontor i Uppsala.
2023-02-08 17:30:00

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER REGARDING ANY SECURITIES IN LIDDS AB. SEE ALSO THE “IMPORTANT INFORMATION” SECTION BELOW.

LIDDS AB (publ) (”LIDDS”or the ”Company”) today announces the final outcome of the rights issue with preferential rights for the shareholders (the ”Rights Issue”), which subscription period ended 6 February 2023. The subscription breakdown shows that 25,253,268 shares, corresponding to approximately 72.7 percent of the Rights Issue, were subscribed for with or without the exercise of subscription rights, of which 20,688,813 shares, corresponding to approximately 59.6 percent of the Rights Issue, were subscribed for through the exercise of subscription rights, and 4,564,455 shares, corresponding to 13.1 percent of the Rights Issue, were subscribed for without the exercise of subscription rights. Thereby, the bottom guarantors are allocated approximately 8.6 percent of the Rights Issue, and the top guarantor approximately 14.4 percent of the Rights Issue, whereby the Rights Issue is subscribed to approximately 95.7 percent in total and LIDDS thereby obtain approximately 46.5 MSEK before issue costs. Those who have been allocated shares without the support of subscription rights will shortly be notified by settlement note or alternatively via their nominee.

The subscription period in the Rights Issue ended on 6 February 2023 and a final outcome shows that, approximately 35.4 MSEK of the Rights issue, was subscribed for with or without the exercise of subscription rights, corresponding to approximately 72.7 percent of the Rights issue, of which 20,688,813 shares, corresponding to approximately 20.7 MSEK or approximately 59.6 percent of the Rights Issue, was subscribed for through the exercise of subscription rights and 4,564,455 shares, corresponding to approximately 6.4 MSEK or approximately 13.1 percent of the Rights Issue, was subscribed for without the exercise of subscription rights. Thereby, the bottom guarantors are allocated approximately 8.6 percent of the Rights Issue, and the top guarantor approximately 14.4 percent of the Rights Issue. LIDDS obtain approximately 46.5 MSEK before issue costs.

Allocation in the Rights Issue
Those who have subscribed for shares without the exercise of subscription rights have been allocated shares in accordance with the principles stated in the prospectus published by the Company on January 17, 2023. In the event of allocation, the settlement note is expected to be sent out around February 9, 2023. Subscribed and allocated shares must be paid in cash in accordance with the instructions on the settlement note. Nominee registered shareholders will be notified of allocation in accordance with the nominee routines.

Dilution due to the Rights Issue
After registration of the Rights Issue at the Swedish Companies Registration Office, the Company's share capital will increase by approximately 1,761,440.69 SEK to a total of approximately 3,602,649.61 SEK. The number of shares in the Company will increase by 33,234,730 to a total of 67,974,521. Shareholders who have not participated in the Rights Issue have thus had their ownership in LIDDS diluted by approximately 48.9 percent.

Trading in paid subscribed shares
Trading in paid subscribed shares (“BTA”) will take place on Nasdaq First North Growth Market until the week after the Rights Issue has been registered with the Swedish Companies Registration Office. Registration of the Rights Issue is expected to take place during week 8, 2023.

Advisors
Erik Penser Bank AB is financial advisor to LIDDS in connection with the share issue and Setterwalls Advokatbyrå AB is legal advisor.